GeoVax Labs, Inc. is advancing its GEO-MVA vaccine targeting Mpox and smallpox through an expedited regulatory pathway with favorable input from the European Medicines Agency. This development addresses the increasing global threat as Mpox cases rise across the United States, Europe, and parts of Africa, highlighting the need for diverse vaccine supply options and enhanced epidemic response capabilities. The vaccine's modern platform promises improved production flexibility and swift adaptation to public health emergencies.
David Dodd, Chairman and CEO of GeoVax, emphasized the importance of ending the current monopoly of MVA-vaccine supply to benefit global public health. The company's recent achievements include favorable Scientific Advice from the EMA and a proposal under the Biomedical Advanced Research and Development Authority’s Rapid Response Partnership Vehicle, positioning GEO-MVA as a viable solution for pandemic preparedness and biodefense objectives. These regulatory and partnership advancements accelerate the vaccine's development while supporting broader stockpile planning initiatives.
The expedited pathway not only addresses urgent public health needs but also creates revenue-generating opportunities for GeoVax as it moves toward commercialization. This progress reflects the company's commitment to addressing high-consequence threats and fulfilling unmet medical needs through innovative vaccine solutions. The GEO-MVA vaccine's development represents a critical step in expanding global vaccine supply options and enhancing preparedness for future outbreaks of Mpox and related orthopoxviruses.
